Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.54 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | KYNU | Q16719 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGAV | P06756 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174139 | 1.00 | ECE1 (0.54) | ECE1MMETACR1KYNUPPARA | |
| SCHEMBL21174225 | 1.00 | ECE1 (0.54) | ECE1MMETACR1KYNUPPARA | |
| SCHEMBL56605 | 0.99 | ECE1 (0.53) | ECE1MMETACR1KYNUPPARA | |
| SCHEMBL21174062 | 0.92 | TACR1 (0.53) | ECE1MMETACR1KYNUCTSK | |
| SCHEMBL21174049 | 0.92 | TACR1 (0.53) | ECE1MMETACR1KYNUCTSK | |
| SCHEMBL56432 | 0.92 | TACR1 (0.53) | ECE1MMETACR1KYNUCTSK | |
| SCHEMBL3171832 | 0.91 | ECE1 (0.57) | ECE1MMETACR1KYNUPPARA | |
| SCHEMBL13530114 | 0.91 | ECE1 (0.57) | ECE1MMETACR1KYNUPPARA | |
| SCHEMBL3354986 | 0.90 | KYNU (0.63) | TACR1KYNUCTSKSIRT2SIRT1 | |
| SCHEMBL56606 | 0.88 | TACR1 (0.50) | TACR1KYNUCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| EP-3514160-B1 | NAHLSGEN OPTICAL RESOLUTION METHOD | UNIV KYOTO (JP) | 2021-08-11 | — | — | EP | disclosed |
| US-10774098-B2 | Nahlsgen optical resolution method | KYOTO UNIVERSITY (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | KYOTO UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| EP-3514160-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | Kyoto University (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-8129557-B2 | Phosphonic acid diester derivative and method for producing thereof | Nagai, Kazuhiro (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | HIRATAKE, GOU (JP) | 2009-06-25 | — | — | US | disclosed |
| WO-2008137446-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774098-B2 | Nahlsgen optical resolution method | HACL2, HAO2, HPD | ECE1 3743/4885MME 2245/4885TACR1 2595/4885 |
| US-20090163725-A1 | PHOSPHONIC ACID DIESTER DERIVATIVE AND METHOD FOR PRODUCING THEREOF | PPA1, G6PD, PHOSPHO1 | ECE1 1671/4885MME 3874/4885TACR1 3099/4885 |
| US-20190225634-A1 | NAHLSGEN OPTICAL RESOLUTION METHOD | HACL2, HAO2, HPD | ECE1 3743/4885MME 2245/4885TACR1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.